Research Use of Ecological Momentary Assessment for Adverse Event Monitoring Following Amyloid-β Results Disclosure

Meghan K Mattos, Susan M Sereika, Scott R Beach, Hyejin Kim, William E Klunk, Melissa Knox, Neelesh K Nadkarni, Lisa S Parker, J Scott Roberts, Richard Schulz, Lisa Tamres, Jennifer H Lingler, Meghan K Mattos, Susan M Sereika, Scott R Beach, Hyejin Kim, William E Klunk, Melissa Knox, Neelesh K Nadkarni, Lisa S Parker, J Scott Roberts, Richard Schulz, Lisa Tamres, Jennifer H Lingler

Abstract

As calls for transparency in human subjects research grow, investigators conducting Alzheimer's disease (AD) biomarker research are increasingly required to consider their ethical obligations regarding the return of AD biomarker test results to research participants. When disclosing these test results to potentially vulnerable participants, investigators may face unique challenges to identify adverse events, particularly psychological events. The purpose of this paper is to describe our research team's experience with developing and implementing a process for enhanced adverse event monitoring following the return of amyloid-β (Aβ) imaging results to research participants with mild cognitive impairment (MCI). Ethical and logistical considerations are presented along with preliminary findings from an ongoing randomized controlled trial of Aβ imaging results disclosure in MCI. Following receipt of amyloid imaging results, participants underwent 14 days of adverse event monitoring using ecological momentary assessment (EMA), a strategy to capture health, behaviors, and mood as they occur in participants' natural settings in real time. EMA telephone calls were placed at random during waking hours to screen for mood changes. Investigators were alerted for positive depression, anxiety, suicidal ideation screenings, or for two days of failed call attempts. Preliminary feasibility of twenty-four participants with MCI who participated in EMA mood assessments was successfully completed 83% (SD = 0.4) of the time over 14 days with no alerts for anxiety or depression screening items. EMA, when used with standard adverse event monitoring, is a promising and novel approach to maximize early detection of negative psychological reactions following AD biomarker results disclosed in research settings.

Keywords: Amyloid; cognitive dysfunction; ecological momentary assessment; ethics; research subjects.

Conflict of interest statement

Authors’ disclosures available online (https://www.j-alz.com/manuscript-disclosures/19-0091r2).

Figures

Fig.1
Fig.1
Ecological momentary mood assessment questionnaire items.
Fig.2
Fig.2
Individual patient health questionnaire-4 response profiles by amyloid-β status (N = 24).
Fig.3
Fig.3
Mean PHQ-2 depressive symptoms for the total sample (N = 24).

References

    1. Rabinovici GD, Jagust WJ (2009) Amyloid imaging in aging and dementia: Testing the amyloid hypothesis in vivo. Behav Neurol 21, 117–128.
    1. Grill JD, Johnson DK, Burns JM (2013) NIH Public Access. Neurodegener Dis Manag 3, 43–51.
    1. Lingler JH, Klunk WE (2013) Disclosure of amyloid imaging results to research participants: Has the time come? Alzheimers Dement 9, 741–744.
    1. The National Academies of Science Engineering Medicine (2018) Return of Individual-Specific Research Results Generated in Research Laboratories
    1. Burns JM, Johnson DK, Liebmann EP, Bothwell RJ, Morris JK, Vidoni ED (2017) Safety of disclosing amyloid status in cognitively normal older adults. Alzheimers Dement 13, 1024–1030.
    1. Schulz R, Cook TB, Beach SR, Lingler JH, Martire LM, Monin JK, Czaja SJ (2013) Magnitude and causes of bias among family caregivers rating Alzheimer’s disease patients. Am J Geriatr Psychiatry 21, 14–25.
    1. Shiffman S, Stone AA, Hufford MR (2008) Ecological momentary assessment. Annu Rev Clin Psychol 4, 1–32.
    1. Stone A, Shiffman S (1994) Ecological momentary assessment (EMA) in behavioral medicine. Ann Behav Med 16, 199–202.
    1. Cain A, Depp C, Jeste D (2009) Ecological momentary assessment in aging research: A critical review. J Psychiatry Res 43, 987–996.
    1. Moore RC, Depp CA, Loebach J, Lenze EJ (2016) Ecological momentary assessment versus standard assessment instruments for measuring mindfulness, depressed mood, and anxiety among older adults. J Psychiatr Res 75, 116–123.
    1. Wenze SJ, Miller IW (2010) Use of ecological momentary assessment in mood disorders research. Clin Psychol Rev 30, 794–804.
    1. Aan het Rot M, Hogenelst K, Schoevers RA (2012) Mood disorders in everyday life: A systematic review of experience sampling and ecological momentary assessment studies. Clin Psychol Rev 32, 510–523.
    1. Armey MF, Schatten HT, Haradhvala N, Miller IW (2015) Ecological momentary assessment (EMA) of depression-related phenomena. Curr Opin Psychol 4, 21–25.
    1. Spielberger C, Gorsuch R, Lushene R, Vagg P, Jacobs G (1983) Manual for the State-Trait Anxiety Inventory, Consulting Psychologists Press, Palo Alto, CA.
    1. Radloff L (1977) The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1, 385–401.
    1. Beck A, Steer R (1991) BSS: Beck Scale for Suicide Ideation, Psychological Corporation.
    1. Lingler JH, Butters MA, Gentry AL, Hu L, Hunsaker AE, Klunk WE, Mattos MK, Parker LA, Roberts JS, Schulz R (2016) Development of a standardized approach to disclosing amyloid imaging research results in mild cognitive impairment. J Alzheimers Dis 52, 17–24.
    1. Lawson K, Wiggins S, Green T, Et A (1996) Adverse psychological events occurring in the first year after predictive testing for Huntington’s disease. J Med Genet 33, 856–862.
    1. Kroenke K, Spitzer RL, Williams JBW, Löwe B (2009) An ultra-brief screening scale for anxiety and depression: The PHQ-4. Psychosomatics 50, 613–621.
    1. Heinz M, Martin P, Margrett JA, Yearns M, Franke W, Yang H-I, Wong J, Chang CK (2013) Perceptions of technology among older adults. J Gerontol Nurs 39, 42–51.
    1. Wendler D, Emanuel E (2003) The debate over research on stored biological samples. Arch Intern Med 162, 1457.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する